Knee osteoarthritis. Gonarthrosis [arthrosis of knee]
Conditions
Interventions
Intervention 1: Intervention group 1: plasma rich in growth factor, knee intraarticular injection, 4 to 6 milliliter, 2 times, 3 weeks interval. Intervention 2: Intervention group 2: platelet rich in
Treatment - Drugs
Intervention group 1: plasma rich in growth factor, knee intraarticular injection, 4 to 6 milliliter, 2 times, 3 weeks interval
Intervention group 2: platelet rich in plasma , knee intraarticular injection, 4 to 6 milliliter, 2 times, 3 weeks interval
Intervention group 3: Hyaluronic acid (500,000 to 730000 Daltons),3times, weekly
Intervention group 4: Ozone Gas, knee intraarticuar injection,10 ml with a concentration of 30 µg per cc 3 times, weekly
Sponsors
Vice chancellor for research, Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
All
Age
50 Years to 70 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Patients with knee osteoarthritis according to the American College of Rheumatology criteria aged between 50-70 years and with symptoms that have been diagnosed for more than 3 months and radiologic evidence of articular damage (grade 1-4 of Kellgren-Lawrence scale) Exclusion criteria: 1- systemic diseases such as diabetes mellitus, Immunodeficiency and collagen vascular disorders 2- history or presence of cancer or malignant disorders 3- any infection and active wound of the knee 4-presence of autoimmune diseases and platelet disorders 5- use of NSAIDs 2 days before injection 6- treatment with anticoagulant and anti-platelet medications 10 days before injection 7-history of knee articular injections of corticosteroids 3 weeks or use of systemic corticosteroids 2 weeks before injections 8-hemoglobin measures of less than 12 g/dl and platelet counts of less than 150,000 per micro liter 9- recent history of severe trauma to the knee 10-age less than 40 or over 75 years 11- history of vasovagal shock 12-pregnancy and breastfeeding 13- genu valgum/varum greater than 20 degrees 14-Allergy to chicken or egg protein or hypersensitivity to hyaluronate 15-patients treated with ACE inhibitors. 16-G6PD deficiency
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Knee pain. Timepoint: before intervention,6 months & 12months after intervention. Method of measurement: changes of WOMAC and VAS questionnaires scores.;Joint Stiffness. Timepoint: before intervention,6 months & 12months after intervention. Method of measurement: change of WOMAC questionnaire scores.;Function. Timepoint: before intervention,6 months & 12months after intervention. Method of measurement: change of WOMAC questionnaire scores. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactParsaa Ghazi hosseini
Shahid Modarres Hospital
Outcome results
None listed